Physician profile
Morgan Harrison
NPI 1134766280
$544.70
in general payments reported to CMS, 2019-2025
14 companies · $32.74 in 2025
The $32.74 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3.75 · 2023: $426 · 2024: $82.55 · 2025: $32.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $347 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $346.95 |
| Education | $194.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $210.25 | 2023-2024 | Rybrevant, Darzalex, Tecvayli |
| Regeneron Healthcare Solutions, INC. | $49.75 | 2023-2024 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $36.08 | 2023 | |
| Novartis Pharmaceuticals Corporation | $34.87 | 2023 | |
| Boston Scientific Corporation | $32.74 | 2025 | Enroute Transcarotid Neuroprotection System |
| Genentech USA, INC. | $22.83 | 2021-2023 | Alecensa, Tecentriq, Gavreto |
| Astrazeneca Pharmaceuticals LP | $22.50 | 2024 | |
| Seagen INC. | $22.18 | 2023 | Adcetris |
| Recordati_rare_diseases_inc. | $21.84 | 2023 | Panhematin |
| Rigel Pharmaceuticals, INC. | $21.33 | 2023 | Rezlidhia, Tavalisse |
| Daiichi Sankyo INC. | $19.38 | 2024 | Injectafer |
| Morphosys, US INC. | $18.81 | 2023 | Monjuvi |
| Incyte Corporation | $17.06 | 2023 | Jakafi |
| Amgen INC. | $15.08 | 2023 | Xgeva, Vectibix, Nplate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.